Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224724 · ClinicalTrials.gov registry record
Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases
A clinical trial of Metastatic Colorectal Carcinoma (mCRC) and Colorectal Cancer Liver Metastases (CRLM), sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07224724 is a study of Metastatic Colorectal Carcinoma (mCRC) and Colorectal Cancer Liver Metastases (CRLM) that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07224724, a study of Metastatic Colorectal Carcinoma (mCRC) and Colorectal Cancer Liver Metastases (CRLM), is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed. The liver is the most frequent and prognostically important site of metastasis, and patients responding well to chemotherapy may become candidates for curative hepatic resection. However, the presence of extrahepatic metastasis (EHM) critically influences treatment eligibility and survival. Although clinical scores such as the Fong and Beppu systems include EHM as a determinant, its detection by imaging remains limited, especially for small or occult lesions. Accurate identification of EHM is also essential when considering liver transplantation for unresectable colorectal liver metastases (CRLM), where EHM remains an exclusion criterion. The EXELION Study aims to develop a non-invasive diagnostic model using serum exosomal microRNAs (miRNAs) to detect both hepatic and extrahepatic metastases in patients with CRLM. By integrating circulating miRNA profiling with machine learning-based analysis, this study seeks to supplement imaging diagnostics, improve treatment stratification, and enhance clinical decision-making for metastatic colorectal cancer.
Conditions Studied
Interventions
- OTHER EXELION
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224724
The ClinicalTrials.gov registry entry for NCT07224724 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Colorectal Carcinoma (mCRC) appearing as the primary indexed condition, and to 1 intervention - of which EXELION is the first listed.
NCT07224724 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07224724 about?
NCT07224724 is a clinical study titled "Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases". Colorectal cancer is the third most common malignancy worldwide, and prognosis largely depends on how effectively metastatic disease is managed. The liver is the most frequent and prognostically important site of metastasis, and patients responding well to chemotherapy may become candidates for cura...
What is the current status of trial NCT07224724?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-06-01. Estimated completion is 2026-06-18.
What conditions does trial NCT07224724 study?
This clinical trial studies the following conditions: Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer Liver Metastases (CRLM).
What interventions are being tested in trial NCT07224724?
The interventions under investigation include: EXELION (OTHER).
Who is sponsoring clinical trial NCT07224724?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224724 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Carcinoma (mCRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Colorectal Carcinoma (mCRC)
All registered trials for this condition
Colorectal Cancer Liver Metastases (CRLM)
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.